CAMBRIDGE, Mass.--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced initial positive results from its ongoing Phase 1/2 clinical trial with ALN-CC5, an ...
It was called ‘complement’ because it aided the antibacterial activity of antibodies. However, it is now known that the complement system can be activated early in an infection without the presence of ...
NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced preliminary Phase 1 multiple ascending dose (MAD) data for RLYB116, an innovative, long-acting, low volume ...
In a recent study posted to the bioRxiv* pre-print server, researchers investigated the complement component 1q (C1q) binding and subsequent complement activation by neutralizing antibodies (nAbs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results